AINDEX
Markets

Starling Oncology, Inc. (STLN)

STLNNASDAQ-CMMedical/Nursing Services

$4.09

+0.0850 (+2.12%) today

Regular session, Nov 10, 11:50 AM ET

+2.12% 1D
Market cap
$416.63m
P/E
–
EPS, last 4 quarters
$-0.2900
Dividend yield
–
Day range
$3.97 to $4.22
52-week range
$2.32 to $7.13
Average volume
1.86m
Previous close
$4.00

Analysts

3 covering

Buy3 buy, 0 hold, 0 sell

Targets a year out average $9.25, +126.4% from here

$8.00now $4.09$10.00

Earnings

next estimate $-0.0400

Next report

Dec 2025

+25.0%

Mar 2026

+71.4%

Jun 2026

-14.3%

Sep 2026

-85.7%

estimate reported, and the surprise

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue$141.96m$147.44m$161.28m$169.77m
Gross profit$22.77m$23.32m$27.16m$30.67m
Operating income-$6.91m-$6.51m-$4.62m-$2.98m
Net income-$7.51m-$2.49m-$9.79m-$15.75m

Last four quarters: revenue $620.45m, margin -5.7%, free cash flow $18.83m

News

8 latest

The company

Founded in 2007, Starling Oncology, Inc. (NASDAQ: STLN) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute , Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.2 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, Starling Oncology is coordinating cancer care for the better.

Sector
Health Care
Industry
Medical/Nursing Services
Exchange
NASDAQ-CM
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.